美多芭与普拉克索治疗帕金森病的疗效分析

Observation of curative effect of metopar and dopamine receptor agonist in patients with Parkinson's disease

目的探讨美多芭与多巴胺受体激动剂普拉克索治疗帕金森病的临床疗效,并观察其对患者运动功能及日常活动能力的影响,为患者临床高效、安全用药提供参考。方法截选医院2012-08—2015-10 78例诊断为帕金森病的患者,按照随机数字表法分为对照组(美多芭62.5mg/次,3次/d,4周后增加为125mg/次,每6h服用1次)与治疗组(美多芭62.5 mg/次,3次/d,4周后增加为125mg/次,每6h服用1次;普拉克索0.125mg/次,2次/d,4周可增加至0.25mg/次,3次/d)各39例;共治疗12周。于治疗12周后分别评价2组患者临床疗效,并采用帕金森病综合评分量表(UPDRS)分别评价2组患者治疗前、治疗8周及12周时日常生活能力(UPDRS II)、运动障碍(UPDRS III)及并发症(UPDRS IV)情况,统计2组治疗期间不良反应情况。结果治疗组优良率为87.18%(34/39)明显高于对照组58.97%(23/39)(χ2=8.04,P=0.01)。2组患者治疗8周、12周时UPDRS II、UPDRS III及UPDRS IV评分均较治疗前明显下降,且治疗12周时UPDRS II、UPDRS III及UPDRS IV评分明显低于治疗8周时,治疗组治疗8周、12周时UPDRS II、UPDRS III及UPDRS IV评分明显低于对照组(P<0.05)。治疗组治疗期间不良反应10.26%(4/39)明显低于对照组30.77%(12/39)(χ2=5.03,P=0.02)。结论采用美多芭联合多巴胺受体激动剂普拉克索治疗帕金森病可有利于改善患者运动功能障碍及日常生活能力,同时还可减少并发症及不良反应,因此值得推荐为临床帕金森病治疗的首选药物。

Objective To investigate the clinical efficacy of methadone and dopamine receptor agonist in Parkinson＇s disease patients,and to observe its effect on the motor function and daily activities of patients, so as to provide a reference for clinical effec rive and safe use of drugs. Methods 78 patients with Parkinson＇s disease were divided into control group （62. 5 mg/d,3 times/d, and 125 mg after 4 weeks,once every 6 h） and the treatment group （62.5 rag/d,3 times/d,4 weeks after the increase of 125 rag/ time, taking every 6 h l dopamine receptor agonist Lyclone 0. 125 mg/time, 2 times/d, 4 weeks can be increased to 0.25 mg/time, 3 times/d） according to the random number table method, each group with 39 cases; After 12 weeks of treatment, the clinical efficacy of the two groups was evaluated, and the UPDRS was used to evaluate the therapeutic effect on the daily living ability, （UPDRS II）, the motor deficiency （UPDRS III） and complication （UPDRS IV） on the patients before treatment, 8 weeks and 12 weeks after treatment respectively. Results The rate of excellent and good treatment in the treatment group was 87. 18% （34/ 39）, which was significantly higher than that in the control group （58.97%, x^2 =8.04 ,P =0. 01 ）. The UPDRS II, UP/）RS III and UPDRS IV scores were significantly lower in the two groups at 8 and 12 weeks, and these scores were significantly lower in 12 weeks than that of 8 weeks. The scores of UPDRS II,UPDRS III and UPDRS IV in the treatment group were significantly lower than those of the control group at 8 and 12 weeks,P〈0.05. In the treatment group, the adverse reactions （10.26 % （4/39） ） was significantly lower than the control group （30.77%,x^2 =5.03,P =0.02）. Conclusion The combination of methadone and dopa mme receptor agonist pramipexole in patient reduce complications and adverse reactions,i